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Abstract Antigen-specific cancer immunotherapy is a
promising strategy for improving cancer treatment.
Recently, many tumor-associated antigens and their epitopes
recognized by cytotoxic T lymphocytes (CTLs) have been
identified. However, the density of endogenously presented
antigen-derived peptides on tumor cells is generally sparse,
resulting in the inability of antigen-specific CTLs to work
effectively. We hypothesize that increasing the density of an
antigen-derived peptide would enhance antigen-specific
cancer immunotherapy. Here, we demonstrated that intra-
tumoral peptide injection leads to additional peptide loading
onto major histocompatibility complex class I molecules of
tumor cells, enhancing tumor cell recognition by antigen-
specific CTLs. In in vitro studies, human leukocyte antigen
(HLA)-A*02:01-restricted glypican-3144–152 (FVGEFFTDV)
and cytomegalovirus495–503 (NLVPMVATV) peptide-spe-
cific CTLs showed strong activity against all peptide-pulsed
cell lines, regardless of whether the tumor cells expressed the
antigen. In in vivo studies using immunodeficient mice,
glypican-3144–152 and cytomegalovirus495–503 peptides injec-
ted into a solid mass were loaded onto HLA class I molecules
of tumor cells. In a peptide vaccine model and an adoptive cell
transfer model using C57BL/6 mice, intratumoral injection of
ovalbumin257–264 peptide (SIINFEKL) was effective for
tumor growth inhibition and survival against ovalbumin-
negative tumors without adverse reactions. Moreover, we
demonstrated an antigen-spreading effect that occurred after
intratumoral peptide injection. Intratumoral peptide injection
enhances tumor cell antigenicity and may be a useful option
for improvement in antigen-specific cancer immunotherapy
against solid tumors.
Keywords Intratumoral peptide injection  Antigen 
Immunotherapy  Cytotoxic T lymphocyte
Abbreviations
CTL Cytotoxic T lymphocyte
HLA Human leukocyte antigen
GPC3 Glypican-3
HCC Hepatocellular carcinoma
MHC Major histocompatibility complex
CMV Cytomegalovirus
HIV Human immunodeficiency virus
OVA Ovalbumin
TAP Transporter associated with antigen
processing
FBS Fetal bovine serum
IFN Interferon
ELISPOT Enzyme-linked immunospot
IFA Incomplete Freund’s adjuvant
PBMC Peripheral blood mononuclear cell
Introduction
Conventional modalities of cancer treatment, including
surgery, radiotherapy, and chemotherapy, have made
advancements in recent years, and the survival rate of cancer
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patients has gradually improved; however, these therapies
remain far from being satisfactory in most cancers [1, 2].
Therefore, the development of novel treatment modalities,
including antigen-specific cancer immunotherapies with
peptide vaccines, dendritic cell vaccines, and adoptive cell
transfer therapies, is critical for advancing effective cancer
treatments [3–5]. While many tumor-associated antigens and
epitopes recognized by cytotoxic T lymphocytes (CTLs)
have been explored as possible antigen-specific cancer
immunotherapies, the results of several anticancer immu-
notherapy clinical trials have been disappointing [6, 7]. We
conducted a clinical trial using the glypican-3 (GPC3) pep-
tide vaccine in advanced hepatocellular carcinoma (HCC)
patients. While this carcinoembryonic antigen overexpres-
sed in HCC seemed to be an ideal target for anticancer
immunotherapy [8–15], only immunological efficacy was
apparent [16], whereas the clinical benefit was limited in
patients [17]. Therefore, the establishment of an innovative
strategy to link the antitumor immune response with the
clinical response and to enhance the power of antigen-spe-
cific cancer immunotherapy is urgently required.
In the antigen-specific cancer immunotherapy concept,
antigen-specific CTLs recognize and destroy tumor cells that
present antigen-derived peptides using cell surface major
histocompatibility complex (MHC) class I molecules. How-
ever, the density of the antigen-derived peptide endogenously
presented on tumor cells is generally low, resulting in the
ineffectiveness of antigen-specific CTLs [18]. This low den-
sity of presented antigen is one reason why antigen-specific
cancer immunotherapy has been ineffective in clinical set-
tings. One solution for overcoming this critical problem is to
induce high-avidity CTLs. Such CTLs can recognize a smaller
number of peptide–MHC class I complexes and would con-
tribute to a better outcome [19]. Another solution is to enhance
tumor cell antigenicity by means of additional peptide loading
onto MHC class I molecules. Increasing the density of anti-
gen-derived peptide would facilitate CTL recognition and
destruction of the tumor cells.
In this study, we investigated whether intratumoral pep-
tide injection would induce additional peptide loading onto
tumor cells, and, if so, whether increased presentation would
enhance antigen-specific CTL tumor cell recognition.
Moreover, we evaluated whether intratumoral peptide
injection could be a useful option for improvement in anti-
gen-specific cancer immunotherapy against solid tumors.
Materials and methods
Synthetic peptides
The peptides used in this study were as follows: human
leukocyte antigen (HLA)-A*02:01-restricted GPC3144–152
(FVGEFFTDV) peptide (American Peptide Company,
Sunnyvale, CA), HLA-A*24:02-restricted GPC3298–306
(EYILSLEEL) peptide (American Peptide Company),
HLA-A*02:01-restricted cytomegalovirus (CMV)495–503
(NLVPMVATV) peptide (ProImmune, Rhinebeck, NY,
USA), HLA-A*24:02-restricted CMV341–349 (QYDP-
VAALF) peptide (ProImmune), HLA-A*02:01-restricted
human immunodeficiency virus (HIV)77–85 (SLYNTYATL)
peptide (ProImmune), and H-2 Kb-restricted ovalbumin
(OVA)257–264 (SIINFEKL) peptide (AnaSpec, Fremont,
CA, USA). The peptides were dissolved and diluted in 7 %
NaHCO3.
Cell lines
T2 cells (HLA-A*02:01), which lack the transporter asso-
ciated with antigen processing (TAP), were purchased from
Riken Cell Bank (Tsukuba, Japan). The human liver cancer
cell line HepG2 (GPC3?, HLA-A*02:01/A*24:02) was
purchased from American Type Culture Collection
(Manassas, VA, USA). The human liver cancer cell line SK-
Hep-1 (GPC3-, HLA-A*02:01/A*24:02), human colon
cancer cell line SW620 (GPC3-, HLA-A*02:01/A*24:02),
murine lymphoma cell line RMA (OVA-, H-2 Kb), EL4
(OVA-, H-2 Kb), and EG7 (OVA?, H-2 Kb) were kindly
provided by Dr. Yasuharu Nishimura (Kumamoto Univer-
sity, Kumamoto, Japan). SK-Hep-1/GPC3 is an established
stable GPC3-expressing cell line transfected with a human
GPC3 gene, and SK-Hep-1/vec is an established counterpart
cell line, in which an empty vector was transfected. EG7 cells
are OVA-transfected EL4 cells. Cells were cultured at 37 C
in RPMI 1640 or DMEM medium (Sigma-Aldrich, St. Louis,
MO, USA) supplemented with 10 % fetal bovine serum
(FBS), 100 U/ml penicillin, and 100 lg/ml streptomycin in a
humidified atmosphere containing 5 % CO2.
Mice
Female BALB/c nude, NOD/SCID, and C57BL/6 mice
(6–8 weeks old) were purchased from Japan Charles River
Laboratories (Yokohama, Japan). OT-I mice [20], which
are CD8? T-cell TCR transgenic mice expressing the TCR
a-chain recognizing OVA257–264 peptide in H-2 K
b, were
kindly provided by Dr. Takashi Nishimura (Hokkaido
University, Sapporo, Japan). All animal procedures were
performed according to the guidelines for the Animal
Research Committee of the National Cancer Center, Japan.
Preparation of OT-I mouse-derived CD8? CTLs
(activated OT-I CTLs)
Naı¨ve CD8? T-cells were purified from the spleens of OT-I
mice using MACS anti-CD8a (Ly-2) MicroBeads (Miltenyi
Biotec, Bergisch Gladbach, Germany). For in vitro
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activation, naı¨ve OT-I CD8? T-cells were incubated with
irradiated EG7 cells at a 3:2 ratio in 24-well plates for
3 days. Each well contained 2.4 9 106 OT-I CD8? T-cells
plus 1.6 9 106 EG7 cells in 2 ml of RPMI 1640 medium
supplemented with 10 % FBS, penicillin, streptomycin,
and 50 lmol/l 2-mercaptoethanol. Activated OT-I CD8?
T-cells were separated from EG7 cells using anti-CD8a
magnetic beads before adoptive transfer.
IFN-c ELISPOT assay
The BDTM ELISPOT set (BD Biosciences, San Jose, CA,
USA) was used for an interferon (IFN)-c enzyme-linked
immunospot (ELISPOT) assay. CTLs were used as
effector cells, and tumor cell lines with or without a
peptide pulse (10 lg/ml for 1 h) were used as target cells.
Effector cells (1 9 103/well) were incubated with target
cells (1 9 104/well) in 200 ll of RPMI 1640 medium
supplemented with 10 % FBS, penicillin, and streptomy-
cin for 20 h at 37 C in 5 % CO2. The number of spots,
indicating an antigen-specific CTL response, was auto-
matically counted using the Eliphoto system (Minerva
Tech, Tokyo, Japan).
Cytotoxicity assay
The Terascan VPC system (Minerva Tech) was used for
cytotoxicity assays. Target cells were labeled with Calcein-
AM (Dojindo Laboratories, Kumamoto, Japan) solution for
30 min at 37 C, washed three times, distributed to 96-well
culture plates in duplicate, and incubated with effector cells
for 4 h. Fluorescence intensity was measured before and
after the 4-h culture, and antigen-specific cytotoxic activity
was calculated as described previously [16].
Intratumoral peptide injection
In in vivo studies, tumors implanted on the backs of mice
were injected with 50 lg peptide mixed with an equal
volume of incomplete Freund’s adjuvant (IFA, Montanide
ISA-51VG; SEPPIC, Paris, France). The total volume of
solution injected was 100 ll in all experiments.
Tumor excision and isolation of tumor cells
To investigate whether the injected peptide was loaded
onto HLA class I molecules of tumor cells in a solid
mass, an IFN-c ELISPOT assay was performed using
these isolated tumor cells as target cells. Mice were killed
and their dorsal tumors were dissected, cut into small
pieces, and digested with collagenase (1.5 mg/ml) for
20 min at 37 C.
In vivo tumor growth inhibition assay
In a peptide vaccine model, H-2 Kb-restricted OVA257–264
peptide emulsified with IFA (50 lg/100 ll) was intrader-
mally injected at the base of the tail of C57BL/6 mice, five
times at 7-day intervals as described previously [13]. After
vaccination, the induction of H-2 Kb-restricted OVA257–264
peptide-specific CTLs was detected by IFN-c ELISPOT
assay (data not shown). In an adoptive transfer model,
activated OT-I CTL (1 9 107 cells/500 ll) was intrave-
nously injected.
SW620 cells (5 9 106 cells/100 ll) were subcutane-
ously implanted into the backs of BALB/c nude mice; SK-
Hep-1/vec, SK-Hep-1/GPC3, or HepG2 cells (5 9 106
cells/100 ll) were implanted into NOD/SCID mice, and
RMA cells (5 9 104 or 5 9 105 cells/100 ll) were
implanted into C57BL/6 mice. Tumor volume was moni-
tored twice a week and calculated using the following
formula: tumor volume (mm3) = a 9 b2 9 0.5, where a is
the longest diameter, b is the shortest diameter, and 0.5 is a
constant to calculate the volume of an ellipsoid. Mortality
and morbidity were checked daily, and the mice were
maintained until each mouse showed signs of morbidity or
the length or width of the tumors exceeded 30 mm, at
which point they were killed for reasons of animal welfare.
Tetramer staining and flow cytometry analysis
For the analysis of local accumulation of antigen-specific
CTLs, isolated tumor cells, including tumor-infiltrating
lymphocytes, were stained with H-2 Kb OVA Tetramer-PE
(OVA257–264 [SIINFEKL]; MBL, Nagoya, Japan) for
20 min at room temperature and anti-mouse CD8-FITC
(rat monoclonal, clone KT15; MBL) for 20 min at 4 C.
Flow cytometry analysis was carried out using a FACSC-
anto II flow cytometer (BD Biosciences).
Immunohistochemistry
To investigate whether CD8? T-cells infiltrated normal
tissues due to intratumoral peptide injection in a murine
adoptive cell transfer model, we performed immunohisto-
chemical staining of CD8 in tissue specimens from C57BL/
6 mice using monoclonal anti-CD8 antibody (dilution 1:20,
BioLegend, San Diego, CA, USA).
Statistical analysis
Comparisons of spot numbers and tumor volume at the last
time point were performed using the Mann–Whitney U
test. Survival was analyzed according to the Kaplan–Meier
estimate, and differences between groups were compared
using the log-rank test. Differences were considered
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significant at P \ 0.05. Data were analyzed with the sta-
tistical package, Dr. SPSS II (SPSS Japan, Tokyo, Japan).
Results
In vitro CTL activity against peptide-pulsed targets
To evaluate the antigen-specific CTL response in vitro,
IFN-c ELISPOT and cytotoxicity assays were performed.
In both assays, the two types of effector cells were the
HLA-A*02:01-restricted GPC3144–152 peptide-specific
CTL clone, which was established from peripheral blood
mononuclear cells (PBMCs) of an HCC patient who had
received the GPC3144–152 peptide vaccine [16], and the
HLA-A*02:01-restricted CMV495–503 peptide-specific CTL
clone, which was established from PBMCs of a healthy
volunteer. The target cells were tumor cell lines with or
without antigenic peptide pulses.
As shown in Fig. 1a, in an IFN-c ELISPOT assay, the
HLA-A*02:01-restricted GPC3144–152 peptide-specific
CTLs produced IFN-c in the presence of GPC3-expressing
tumor cells, HepG2 and SK-Hep-1/GPC3, without peptide
pulse. These effector cells recognized GPC3144–152 antigen
peptide, which is endogenously presented on the cell sur-
face of the non-peptide-pulsed target cells. The number of
IFN-c-producing cells increased dramatically after the
pulse of HLA-A*02:01-restricted GPC3144–152 peptide. In
contrast, GPC3144–152 peptide-specific CTLs did not pro-
duce IFN-c against GPC3-negative tumor cells, SW620
and SK-Hep-1/vec, without peptide pulse. However, a
marked increase in IFN-c-producing cells was detected
against these cell lines after the pulse of HLA-A*02:01-
restricted GPC3144–152 peptide. The IFN-c-producing cells
did not increase after the pulse of HLA-A*24:02-restricted
GPC3298–306 or HLA-A*02:01-restricted HIV77–85 peptide
(Fig. 1a). Similarly, HLA-A*02:01-restricted CMV495–503
peptide-specific CTLs produced IFN-c only in the presence
of HLA-A*02:01-restricted CMV495–503 peptide-pulsed
target cells (Fig. 1b).
In a cytotoxicity assay, HLA-A*02:01-restricted
GPC3144–152 and CMV495–503 peptide-specific CTLs
showed antigen-specific killing activity according to the
peptide density on tumor cells. HLA-A*02:01-restricted
GPC3144–152 peptide-specific CTLs showed specific cyto-
toxicity against HLA-A*02:01-restricted GPC3144–152
peptide-pulsed SW620 and T2 targets, whereas they did not
show cytotoxicity against HLA-A*02:01-restricted
HIV77–85 peptide-pulsed targets (Fig. 1c). In addition,
HLA-A*02:01-restricted GPC3144–152 peptide-specific
CTLs showed apparent but weak cytotoxicity (13–44 %)
against non-peptide-pulsed HepG2 and SK-Hep-1/GPC3
cells, but the cytotoxicity was markedly strengthened
(55–99 %) against all examined cell lines after the HLA-
A*02:01-restricted GPC3144–152 peptide pulse (Fig. 1d).
Similarly, HLA-A*02:01-restricted CMV495–503 peptide-
specific CTLs showed CMV495–503 peptide-specific cyto-
toxicity against all examined cell lines pulsed with
CMV495–503 peptide (Fig. 1e).
The peptide-specific CTLs showed strong activity
against all peptide-pulsed cell lines, regardless of whether
the tumor cells expressed the antigen. The density of the
HLA-A*02:01-restricted GPC3144–152 peptide endoge-
nously presented on tumor cells was not enough to induce
strong CTL activity.
Loading of injected peptide onto HLA class I molecules
of tumor cells in vivo
As shown in Fig. 2a, BALB/c nude mice were inoculated
subcutaneously on their backs with SW620 (GPC3-) tumor
cells. When tumor diameters reached 5–7 mm, 50 lg
HLA-A*02:01-restricted GPC3144–152 peptide was injected
into the tumor. After 2–96 h, the tumors were dissected, cut
into small pieces, and digested with collagenase (1.5 mg/
ml) for 20 min at 37 C. To investigate whether the
injected HLA-A*02:01-restricted GPC3144–152 peptide was
loaded onto HLA class I molecules of tumor cells in a solid
mass, an IFN-c ELISPOT assay was performed in dupli-
cate using these isolated tumor cells as target cells and
HLA-A*02:01-restricted GPC3144–152 peptide-specific
CTLs as effector cells.
Loading of HLA-A*02:01-restricted GPC3144–152 pep-
tide onto HLA class I of tumor cells was detected (Fig. 2b).
Without IFA, the density of loaded peptide gradually
decreased after intratumoral peptide injection, whereas the
loaded peptide density remained for 96 h after injection with
IFA, suggesting that IFA is required for long-term stability of
the injected peptide (Fig. 2c). Similar data were obtained
with a combination of the HLA-A*02:01-restricted
CMV495–503 peptide and its specific CTLs (data not shown).
Antitumor effect of intratumoral peptide injection
in an immunodeficient mouse model
We planned and executed the experimental schedule shown
in Fig. 3a. Four tumors were implanted per mouse, and each
tumor received a different combination of injections, as
shown in Fig. 3b. From 5–7 days after tumor inoculation,
mice were treated two or three times in 5-day intervals. The
treatment regime was as follows: HLA-A*02:01-restricted
GPC3144–152 or CMV495–503 peptide emulsified with IFA
(50 lg/100 ll) was injected into a tumor, and, 2 h later,
HLA-A*02:01-restricted GPC3144–152 or CMV495–503
peptide-specific human CTLs (1 9 107 cells/100 ll) were
injected into the tumor.
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Intratumoral injection of a combination of HLA-
A*02:01-restricted GPC3144–152 peptide and its specific
CTLs resulted in statistically significant tumor growth
inhibition (P \ 0.05) (Fig. 3c). Similarly, this treatment
was effective against SK-Hep-1/vec (Fig. 3d), SK-Hep-1/
GPC3 (Fig. 3e), and HepG2 (Fig. 3f) tumors. Intratumoral
injection of HLA-A*02:01-restricted GPC3144–152 peptide-
specific CTLs alone against GPC3-expressing tumors, SK-
Hep-1/GPC3 and HepG2, was only partially effective,
suggesting that the HLA-A*02:01-restricted GPC3144–152
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peptide endogenously presented on SK-Hep-1/GPC3
and HepG2 tumor cells was not sufficiently dense. How-
ever, intratumoral injection of HLA-A*02:01-restricted
GPC3144–152 peptide increased the peptide density and
markedly enhanced CTL activity. Similarly, intratumoral
injection of HLA-A*02:01-restricted CMV495–503 peptide
followed by its specific CTLs resulted in statistically sig-
nificant tumor growth inhibition (P \ 0.05) (Fig. 3g).
Intratumoral injection of a combination of antigen peptide
and its specific CTLs had a significant antitumor effect.
Therapeutic advantage of intratumoral peptide injection
as an option for antigen-specific cancer immunotherapy
After the induction of OVA257–264 peptide-specific CTLs
by peptide vaccination (Fig. 4a) or after the adoptive
transfer of OVA257–264 peptide-specific CTLs (Fig. 4c),
intratumoral injection of OVA257–264 peptide was effective
against RMA cells, which are OVA-negative tumor cells.
The RMA tumors cells that were injected intratumorally
with OVA257–264 peptide demonstrated significant tumor
growth inhibition, compared with mice without intratu-
moral injection of OVA257–264 peptide (P \ 0.05). The
survival rate in the treatment group was significantly better
than that in the control groups (P \ 0.05) (Fig. 4b, d). The
group that did not receive OVA257–264 peptide vaccine but
that received intratumoral peptide injection showed a par-
tial treatment effect (Fig. 4b).
To obtain direct evidence that intratumoral peptide
injection leads to local accumulation of antigen-specific
CTLs, an OVA tetramer assay was performed using an
adoptive cell transfer model (Fig. 4e). Two RMA tumors
were bilaterally implanted per mouse. One tumor was
injected with the OVA257–264 peptide plus IFA, and the
other tumor with IFA alone (Fig. 4f). As shown in Fig. 4g,
the tumor that underwent both adoptive cell transfer of
activated OT-I CTLs and intratumoral injection of the
OVA peptide contained more OVA-specific CTLs than the
other tumors. Local accumulation of OVA-specific CTLs
after intratumoral injection of the OVA257–264 peptide was
confirmed by OVA tetramer assay.
Neither toxic signs nor death due to intratumoral injection
of the OVA257–264 peptide was observed. Moreover, to
evaluate the risk of autoaggression by intratumoral peptide
injection, the tissues of treated mice in an adoptive cell
transfer model were pathologically examined. The spleen,
brain, lung, heart, liver, kidney, and tumor were critically
scrutinized, and the findings were compared with those from
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mice that had intratumoral injection with IFA alone. In mice
treated with intratumoral injection of OVA257–264 peptide, a
larger number of CD8? T-cells had infiltrated the RMA
tumor 24 days after the transfer of OT-I CTLs and 10 days
after the last intratumoral injection of OVA257–264 peptide.
However, the simultaneous infiltration of normal tissues by
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Fig. 3 Antitumor effect of intratumoral peptide injection in an
immunodeficient mouse model. Intratumoral injection of a combina-
tion of antigen peptide and its specific CTLs had a significant
antitumor effect. a Treatment schedule. b Experimental schematic
representation. BALB/c nude mice or NOD-SCID mice were
inoculated subcutaneously on their back with SW620, SK-Hep-1/
vec, SK-Hep-1/GPC3, or HepG2 tumor cells. Four tumors were
implanted per mouse, and HLA-A*02:01-restricted GPC3144–152 or
CMV495–503 peptide emulsified with IFA (50 lg/100 ll) and HLA-
A*02:01-restricted GPC3144–152 or CMV495–503 peptide-specific
human CTLs (1 9 107 cells/100 ll) were injected into each tumor.
(c, d, e, f, and g) Tumor volume. Tumor growth was expressed by
mean tumor volume; bars (SD). Seven mice were used in each
experiment. Arrows indicate the days when treatment was performed.
*P \ 0.05 compared with treatment group (Mann–Whitney U test)
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Fig. 4 Therapeutic advantage of intratumoral peptide injection as an
option for antigen-specific cancer immunotherapy. (a and b) Peptide
vaccine model. (c and d) Adoptive cell transfer model. (a and
c) Treatment schedule. (b and d) Tumor growth and Kaplan–Meier
survival curves. Tumor growth was expressed by mean tumor
volume; bars (SD). *P \ 0.05 compared with the treatment group
(Mann–Whitney U test). The survival of mice in the treatment group
was significantly better than that in the control groups (P \ 0.05)
(log-rank test). Five mice were used in each group. e Schedule for
analysis of local accumulation of OVA-specific CTLs in an adoptive
cell transfer model. f Experimental schematic representation. Two
tumors were implanted per mouse (5 9 104 cells/100 ll). One tumor
was injected with the OVA peptide plus IFA, and the other with IFA
alone. g OVA tetramer assay. Local accumulation of OVA-specific
CTLs was confirmed in a tumor injected with the OVA peptide plus
IFA. Data are representative of three independent experiments.
h Immunohistochemical staining of CD8 in tumor and normal tissues.
Spleen was used as positive control. Scale bars, 50 lm
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CD8? T-cells was not observed (Fig. 4h). These results
suggest that peptide from intratumoral injection did not
spread into normal tissues.
The effect of antigen spreading to another tumor
after intratumoral peptide injection
Using an adoptive cell transfer model, we assessed the
possibility of antigen-spreading effect after intratumoral
peptide injection, as depicted in Fig. 5a. Two RMA tumors
were bilaterally and metachronously implanted per mouse,
and only the first tumors received intratumoral injection of
the OVA257–264 peptide. The sizes of the second tumors
were compared with those from mice that received intra-
tumoral injection of IFA alone (Fig. 5b). Whereas the
second tumors were established 14 days after the second
tumor inoculation in three out of four control mice, all four
peptide-loaded mice that had received intratumoral
OVA257–264 peptide injection into their first tumor com-
pletely rejected the challenge of the second tumor, which
did not receive intratumoral OVA257–264 peptide injection
itself (Fig. 5c).
To confirm the hypothesis of antigen spreading, an IFN-c
ELISPOT assay was performed. RMA tumor-bearing
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C57BL/6 mice that had received adoptive transfer of
OT-I CTLs and intratumoral injection of OVA257–264
peptide were killed, and their spleens were obtained
21 days after adoptive transfer and 7 days after the last
intratumoral injection. CD8? T-cells, isolated from the
spleen cells using anti-CD8a magnetic beads, were
incubated with irradiated RMA cells for 3 days. CD8?
T-cells were separated from RMA cells using anti-CD8a
magnetic beads before the assay. An IFN-c ELISPOT
assay was performed in duplicate using CD8? T-cells as
effector cells and RMA cells as target cells (Fig. 5d).
The mice that had received intratumoral injection of
OVA257–264 peptide showed a significant response to
OVA-negative RMA tumor cells compared with control
mice that had received intratumoral injection of IFA
alone (P \ 0.05). The observed induction of RMA-
derived antigen-specific CTLs provides evidence that
antigen spreading occurred by treatment with intratu-
moral OVA257–264 peptide and intravenous OT-I CTLs
(Fig. 5e).
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Fig. 4 continued
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Discussion
We demonstrated that intratumoral peptide injection leads
to additional peptide loading onto MHC class I molecules
of tumor cells, causing enhanced CTL recognition of tumor
cells. It is likely that a larger number of antigen-specific
CTLs infiltrate the tumors after this procedure, and tumor
cells are killed more easily because CTL activity depends
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Fig. 5 Effect of antigen-spreading to another tumor after intratu-
moral peptide injection. a The schedule for the experiment on
antigen-spreading effect in an adoptive cell transfer model. b Exper-
imental schematic representation. Two tumors were metachronously
implanted per mouse (first tumor: 5 9 104 cells/100 ll, second
tumor: 5 9 105 cells/100 ll), and only the first tumor (right back)
received intratumoral peptide injection. The second tumor (left back)
was not treated, but was observed. c The growth of the second
inoculated RMA tumor. Four lines indicate the tumor growth of each
mouse. All four mice in the treatment group completely rejected the
second tumor challenge. d The experiment schedule to confirm
antigen spreading. e IFN-c ELISPOT assay. EL4 cells were used as
negative control targets. The data are expressed as mean values of
three mice (SD). *P \ 0.05 compared with control (Mann–Whitney
U test)
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on the peptide density of tumor cells in an HLA class
I-restricted manner. In other words, intratumoral peptide
injection enhances the antigenicity of tumor cells, regard-
less of whether the tumor cells originally expressed the
antigen. To the best of our knowledge, this is the first study
to show the efficacy of intratumoral peptide injection in
detail. A previous report demonstrated that peptide injection
around a tumor assisted the activity of low-avidity CTLs in
an immunodeficient mouse model [21]. In addition, we
demonstrated the advantage as a therapeutic modality
combined with antigen-specific cancer immunotherapy
without any adverse reactions associated with this proce-
dure in mice. Intratumoral peptide injection can strengthen
the efficacy of every kind of antigen-specific cancer
immunotherapy and may be a useful therapeutic option.
This is the first study to describe anticancer treatment
with CMV-derived peptide-specific CTLs. Virus-derived
antigens, which are exogenous antigens, usually have
stronger antigenicity than tumor-associated autoantigens.
Therefore, virus-derived antigen-specific CTLs are easier
to induce [22]. Theoretically, every kind of antigen is
applicable to our procedure unless it is expressed in healthy
human cells. However, it is unclear whether post-CMV-
infected lesions are safe from CMV-specific CTL cyto-
toxicity. Further investigations are necessary regarding the
possible clinical use of exogenous antigens, such as CMV-
derived peptides.
We used NaHCO3, which is known to have therapeutic
effects against tumors [23, 24], as a peptide diluent. How-
ever, our data demonstrated the efficacy of intratumoral
peptide injection, because control animals which under-
went intratumoral injection of IFA alone or IFA plus an
irrelevant peptide also received NaHCO3.
In an in vivo tumor growth inhibition assay using a
peptide vaccine model, the group that did not receive the
OVA257–264 peptide vaccine but that received intratumoral
peptide injections showed a partial treatment effect. This
indicates that intratumoral or peritumoral antigen-present-
ing cells recognized intratumorally injected OVA257–264
peptide and induced OVA257–264 peptide-specific CTLs
after three intratumoral peptide injections. However, we
showed in this study that intratumoral peptide injection
attracted more OVA257–264 peptide-specific CTLs and was
more effective when combined with peptide vaccines or
adoptive cell transfer therapies.
A limitation of intratumoral peptide injection is its
delivery method. First, immunotherapy is expected to
contribute toward cancer therapy especially in the early
stages or in the prevention of recurrence, in which cancer
sites, the so-called ‘‘micro lesions,’’ are undetectable by
imaging modalities. However, intratumoral peptide injec-
tion must be limited to the tumors, which are detectable by
imaging modalities, and can be approached with a needle.
Second, it is difficult to spread the peptides over the whole
tumor by intratumoral injection, especially against large
tumors. Moreover, it is difficult to approach all of the
multiple tumors. This procedure might limit the ability of
immunotherapy as a systemic therapy. If a novel method of
delivering peptides to tumor cells selectively through a
systemic route is established in the future due to advances
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in drug-delivery technologies, this method will become
more suitable for clinical application.
Another limitation is that it requires the presence of
MHC class I molecules. The potential loss of MHC class I
expression in tumors would lead theoretically to the failure
of this approach. Previous reports have indicated that
61–85 % of breast cancers had loss of or decreased HLA
class I expression [25–27]. On the other hand, the down-
regulation of HLA class I was less frequently observed in
other cancers [27–30]. Before clinical application, it is
necessary to select cancers in which HLA class I expres-
sion is sufficiently high.
Antigen-spreading effects have been observed following
anticancer immunotherapy [31–34]. The second tumor
challenge is easily rejected due to immunological memory.
Therefore, we fixed the number of implanted tumor cells as
the second tumors could be established. In this study, we
report evidence of an antigen-spreading effect after intra-
tumoral peptide injection. If this antigen-spreading effect is
sufficiently steady and reliable, intratumoral peptide
injection may even be effective against imaging-invisible
or unapproachable tumors.
In conclusion, intratumoral peptide injection is an
attractive strategy for enhancing tumor cell antigenicity. It
can induce additional peptide loading onto tumor cells,
making tumor cells more antigenic for antigen-specific
CTL activity against tumor cells. Moreover, it may be a
useful option for improvement in antigen-specific cancer
immunotherapy against solid tumors (Fig. 6).
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